Book a strategy conversation
Advising pharma, biotech, CDMOs, cold‑chain and logistics leaders — and their legal counsel — across the UK, EU, and US
Independent Biopharmaceutical Supply‑Chain Strategy
Where pharma supply‑chain practice meets policy
Strategic insight and execution for high‑stakes biopharma value‑chains
PharmaFlow advises companies, regulators, and legal teams on redesigning global supply‑chains, leveraging CDMOs effectively, and treating drug availability as national infrastructure—not a procurement problem.
Led by Hedley Rees, author of Transforming the Pharmaceutical Supply Chain (Wiley, 2025), and former advisor to Lonza, Catalent, Oxford BioMedica, Tower Cold Chain, Marken, and UPS Healthcare on UK advanced manufacturing supply‑chain bids and strategy — alongside Dr Angeliki Kotsianti, former Pfizer physician‑scientist who held final medical judgement on the company’s medicines for nineteen years.
WHO WE WORK WITH
We partner with leadership teams who see supply‑chain design as a strategic capability, not a back‑office function.
- Global pharma and large biotechs managing complex biologics, sterile injectables, and advanced therapy portfolios with multi‑continent CDMO networks
- Scale‑up biotechs preparing for first global launches, process transfers, and regulatory inspections across UK, EU, and US markets
- CDMOs and logistics providers shaping UK/EU advanced manufacturing bids, capacity expansions, and differentiated service models
- Regulators and policymakers developing resilient national supply strategies for critical medicines and advanced therapies
- Solicitors and insurers handling clinical negligence, product liability, or regulatory inquiry cases involving medicine shortages or manufacturing/quality failures
Every engagement pairs Hedley Rees’s supply‑chain and manufacturing expertise with Dr Angeliki Kotsianti’s medical governance and regulatory judgement.
Typical engagements start when boards ask:
“Where are we truly vulnerable?”, “How do we de‑risk this launch or transfer?”, or “What should our UK/EU manufacturing footprint look like in 2030?” — or when legal teams ask: “Why did this shortage happen, and was it foreseeable?”
Clients
One of the most common challenges that our clients face is the difficulty of managing the complexities around drug commercialisation, including keeping up-to-date with regulations, issues with supply, and cold-chain distribution problems.
Due to our decades of experience in the pharmaceutical industry we’re well placed to both consult and educate on how to overcome such issues.